Ischemia reperfusion (IR) injury occurs when blood supply, perfusion, and concomitant reoxygenation is restored to an organ or area following an initial poor blood supply after a critical time period.
Ischemia Reperfusion Injury Therapeutics Market: Introduction
- Ischemia reperfusion (IR) injury occurs when blood supply, perfusion, and concomitant reoxygenation is restored to an organ or area following an initial poor blood supply after a critical time period. It contributes to mortality and morbidity in numerous pathological conditions in emergency medicine clinical practice, including trauma, ischemic stroke, myocardial infarction, and post?cardiac arrest syndrome.
Key Drivers and Restraints of Global Ischemia Reperfusion Injury Therapeutics Market
- Rise in cases of ischemia or a lack of oxygen (anoxia or hypoxia) in organs leads to ischemia-reperfusion injury (IRI), or reoxygenation injury, once blood supply returns to the tissue after a period. According to Global Burden of Disease (GBD) study in 2010, more than 11 million ischemic strokes occurred, while 63% of them were in low- and middle-income countries. Furthermore, nearly 3 million deaths occurred due to ischemic stroke. As per CDC, in 2018, 1 in every 6 deaths from cardiovascular disease was due to stroke in the U.S. Ischemic Heart Disease (IHD) is the first ranked among most common causes of death involving cardiovascular and other diseases. In 2013, the estimated prevalence of IHD among people aged more than 18 years was 6.1%, 6.4%, 5.3%, and 3.7% in Caucasian, African, Latino, and Asian populations, respectively.
- However, high cost of reperfusion injury treatment may hamper the market. Risk factors associated with it, such as hypertension, hyperlipidemia, diabetes, insulin resistance, heart failure, altered coronary circulation and aging, can also hamper the ischemia reperfusion injury therapeutics market.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=79082
Heart injury segment to expand significantly
- Based on indication, the global ischemia reperfusion injury therapeutics market can be divided into: heart injury, kidney injury, intestine injury, and other injury
- The heart injury segment accounted for a prominent share of the global market in 2019. Acute and chronic immune responses increased by myocardial ischemia have an important role in the functional deterioration of the heart. According to Medscape data, approximately 1.5 million cases of myocardial infarction (MI) occur annually in the U.S.
Request for Analysis of COVID-19 Impact on Ischemia Reperfusion Injury Therapeutics Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=79082
Retail pharmacies segment to dominate global ischemia reperfusion injury therapeutics market
- Based on distribution channel, the global ischemia reperfusion injury therapeutics market can be divided into: hospital pharmacies, retail pharmacies and online pharmacies
- In terms of revenue, the retail pharmacies segment held a major share of the market in 2019. It is projected to maintain its position during the forecast period. However, the online pharmacies segment is estimated to expand at a notable CAGR during the forecast period due to an increase in popularity of online pharmacies to obtain prescribed drugs and steady pace of adoption of this distribution channel by customers.
- Increase in the number of therapeutics being dispensed through retail pharmacies and a rise in the number of retail pharmacies in developing countries make retail pharmacies a major channel of distribution
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=79082
North America to dominate global ischemia reperfusion injury therapeutics market
- In terms of region, the global ischemia reperfusion injury therapeutics market can be divided into: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
- In terms of revenue, North America dominated the global ischemia reperfusion injury therapeutics market, followed by Europe. Increase in demand for disease-specific treatment, rise in number of FDA approvals, and numerous product launches in the U.S. contribute to the leading share held by the region. In November 2019, Faraday Pharmaceuticals announced top-line results from its Phase 2 trial of FDY-5301 for the treatment of reperfusion injury following ST elevation myocardial infarction (STEMI).
- Rising healthcare expenditure in developing countries along with an increase in the demand for ischemia reperfusion injury treatment boost is projected to boost the market in Asia Pacific at a significant CAGR during the forecast period
Pre book Ischemia Reperfusion Injury Therapeutics Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=79082<ype=S
Key Manufacturers Operating in Market
The global ischemia reperfusion injury therapeutics market was highly fragmented in 2019. Key manufacturers operating in the global market are:
- Gilead Sciences, Inc.
- Omeros Corporation
- Ensemble Therapeutics Corporation
- Nyken B.V.
- Erimos Pharmaceuticals, LLC
- Opsona Therapeutics Limited
- Curatis Pharma GmbH
- Pharming Group N.V.
- Biomedica Management Corporation
- Orexo AB
- Bolder Biotechnology, Inc.
- PledPharma AB
- Bayer AG
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453